Corcept's Drug Rejection: Market Value Plummets
Update: 2025-12-31
Description
Corcept Therapeutics suffers major blow as FDA rejects drug for rare blood pressure condition, leading to a staggering 47% drop in shares and potentially wiping out billions from the companys market value. CEO Joseph Belanoff expresses disappointment, while the company plans to meet with the FDA to discuss next steps. Despite this setback, Corcept continues to explore relacorilants potential in other areas, such as ovarian cancer. Checkout Solipillow.com
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
